Diabetes Study Finds Genetic Variants May Reduce Ozempic Effectiveness

Ozempic and its family of GLP-1 receptor agonists have changed how doctors treat Type 2 diabetes, with more than a quarter of patients now using these medications. But a new study from Stanford Medicine and an international team of collaborators suggests that genetics may be working against some of these patients without anyone knowing. The findings, published in Genome Medicine, identify a group of genetic variants that appear to cause GLP-1 resistance, a phenomenon in which the body does not respond properly to the hormone.

Stanford Study Identifies Possible Cause of Ozempic Resistance

Researchers may have identified an important factor influencing how patients respond to GLP-1 therapies. About ten percent of the population carries these specific genetic variants, which means millions of people may be getting less benefit from their medication than they deserve. The study focused primarily on blood sugar control rather than weight loss, so the full picture remains incomplete for now. Still, this discovery opens a door toward precision medicine that could match the right patient with the right drug from day one.

The Science Behind GLP-1 Resistance

The research team concentrated on two genetic variants that reduce the activity of an enzyme called PAM, a little-known but crucial player in human biology. This enzyme catalyzes a unique chemical process called amidation, which activates a wide range of hormones, including GLP-1 itself. When PAM does not work correctly, multiple hormone systems may struggle to function as they should. The findings suggest a single genetic variant may influence multiple hormone systems involved in blood sugar regulation and appetite control.

The scientists hypothesized that people with these PAM variants would have lower levels of active GLP-1 because the hormone might fall apart without proper amidation. They recruited volunteers with and without the variant, gave them a sugary drink, and then drew blood every five minutes for four hours. What they found contradicted their original hypothesis.

An Unexpected Discovery About Hormone Levels

The participants with the PAM variant actually showed higher levels of circulating GLP-1, not lower as the team had predicted. Despite those elevated hormone levels, these individuals showed no evidence of better blood sugar control or faster glucose clearance. More GLP-1 did not translate into greater biological activity, suggesting the body had become resistant to the hormone’s effects. The findings suggest that higher circulating GLP-1 levels do not necessarily translate into stronger biological effects when resistance is present.

The researchers spent several years double-checking their results because the finding seemed so counterintuitive. The team joined forces with Zurich-based scientists who had engineered mice missing the PAM gene, and those rodents displayed the identical trend of higher GLP-1 levels paired with diminished efficacy. One of GLP-1’s major jobs is slowing how quickly food leaves the stomach, and the mice without PAM showed faster gastric emptying that the medication could not fix.

Clinical Trials Confirm the Genetic Effect

The team then turned to real-world data from three clinical trials that included over one thousand participants with diabetes. People carrying PAM variants consistently responded less well to GLP-1 receptor agonists than non-carriers. After six months of treatment, about 25% of patients without the variants reached the recommended blood sugar targets.

Among carriers of one particular variant, that number dropped to just 11.5%, a dramatic difference that no doctor should ignore. Did the variants affect other diabetes medications in the same way, or was this problem unique to GLP-1 drugs? The investigators examined how patients responded to sulfonylureas, metformin, and DPP-4 inhibitors and found no meaningful differences between patients with the genetic variants and those without.

This specificity tells the scientists that the resistance mechanism is directly tied to GLP-1 receptor pharmacology rather than to a general metabolic problem. Two additional trials using longer-acting GLP-1 drugs showed no differences between groups, which suggests higher doses or different formulations might overcome the resistance.

What This Means for Patients and Doctors

Diabetes injection pin on the table. — Image of Injection Pin, Courtesy of Haberdoedas via Unsplash.

Anna Gloyn, a professor at Stanford Medicine and senior author of the study, points out that physicians often consider changing a patient’s treatment plan after six months of poor response. Identifying non-responders in advance could help patients skip those wasted months and move directly to a therapy that actually works for their biology.

Mahesh Umapathysivam, who works as both an endocrinologist and a clinical researcher, observes a wide range of patient reactions to GLP-1 drugs daily in his clinic. He calls this research the first step toward using someone’s genetic makeup to improve clinical decision-making. Researchers say physicians currently have limited tools for predicting which patients will respond best to GLP-1 therapies before treatment begins.

The study found no evidence that PAM variants affect weight-loss outcomes, but the data on that front remain too limited to draw any real conclusions. Markus Stoffel, the other senior author from ETH Zurich, notes that large amounts of genetic data from pharmaceutical company trials likely already exist and could answer many remaining questions.

The Million Dollar Question Remains Unsolved

Despite ten years of work across multiple countries, the researchers still cannot explain exactly what causes GLP-1 resistance at a molecular level. Anna Gloyn admits that the team has ticked off an enormous list of possible explanations, and none of them have panned out so far. The variants do not affect how GLP-1 binds to its receptor, nor do they disrupt the initial signaling steps inside the cell. Researchers believe the answer may lie further downstream in biological pathways that are not yet fully understood.

Gloyn compares the situation to insulin resistance, a condition that researchers still do not fully understand despite decades of intense study. Even without a complete mechanistic explanation, doctors have developed effective treatments that help patients overcome insulin resistance. The same path forward likely awaits GLP-1 resistance, with treatments arriving long before scientists fully understand every detail.

Moving Diabetes Care Toward Precision Medicine

This research represents the first detailed examination of GLP-1 resistance, and it opens the door to a more personalized approach for treating Type 2 diabetes. Instead of prescribing the same drug to everyone and waiting to see what happens, doctors could one day use genetic testing to guide their initial choices. The ten percent of patients carrying these variants could skip straight to medications that work better for their particular biology.

Researchers say existing genetic data from clinical trials may help identify additional groups of patients who respond differently to GLP-1 therapies. Gloyn believes those datasets hold valuable insights that could help explain why some patients do not benefit from GLP-1 therapies. The study published in Genome Medicine brings together scientists from multiple countries over a decade of collaboration. Ozempic resistance may still hold its secrets close, but researchers now have a clear map of where to look next.

Additional News from Total Apex Herald

Follow David Gilbert for Entertainment, Gaming, and Current Affairs Coverage

Stay connected with David Gilbert for the latest updates on entertainment, gaming, technology, science, and current affairs.

You can also explore more of David Gilbert’s reporting and analysis across Total Apex Entertainment and Total Apex Herald.